Skip to Content

Zostavax Sales Data

Rank 87 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Zostavax U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 87 (12) 15.17% 20.53%
Q3 2013 99 ()
Q4 2012 70 (14) 14.39% 10.95%
Q3 2012 84 ()

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

December 31, 2015Asthma May Be Linked to Shingles Risk
December 15, 2015Shingles Linked to Raised Heart Risks for Seniors, Study Finds
October 5, 2011Health Tip: Getting the Shingles Vaccine
March 24, 2011U.S. Shingles Vaccine Approval Expanded
January 12, 2011Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease
January 12, 2011Vaccine For Shingles Ailment Effective -- And Seldom Used, Study Says
January 11, 2011Shingles Vaccine Looks Like a Safe Bet for Seniors: Study
May 14, 2010New Large Study Results Confirm Safety Profile of Zostavax, Merck's Shingles Vaccine, in People Aged 60 or Older
February 8, 2010Getting Shingles Vaccine Easier